EVOXX TECHNOLOGIES GMBH

Their core work

EVOXX Technologies is a German biotech SME specializing in the development and industrial application of enzymes, with a particular focus on biocatalysis. Their work bridges the gap between enzyme discovery — including from extreme marine environments — and practical industrial deployment, contributing to platforms for screening, expressing, and scaling up enzyme-based processes. In both H2020 projects, they participated as a specialist contributor, bringing enzyme engineering and industrial bioprocess expertise to large international consortia. Their core value to partners is translating biological enzyme findings into commercially viable catalytic applications.

What they specialise in

How they've shifted over time

Both H2020 projects ran concurrently from 2015 to 2019, so there is no meaningful temporal shift between an early and a late phase — EVOXX participated in both simultaneously. The INMARE project carries all available keywords (marine extremophiles, metagenomics, biocatalysis, bioactive compounds), while ROBOX — despite being the larger grant — has no keyword data, making it impossible to determine whether it represented a broadening or deepening of focus. What can be said is that even within these two parallel projects, EVOXX spanned both bioprospecting from marine sources and the engineering of oxidative enzymes for chemical synthesis, suggesting a deliberately broad industrial enzyme portfolio from the outset.

With both projects running simultaneously in 2015–2019 and no later H2020 activity recorded, it is unclear whether EVOXX continued to grow its EU project portfolio after 2019 or shifted focus to commercial scale-up — prospective partners should verify current activity directly.

How they like to work

EVOXX has never coordinated an H2020 project, always joining as a participant — a pattern consistent with a specialized SME that contributes targeted enzyme expertise rather than managing large consortia. Both projects were Innovation Actions, which are market-oriented and typically involve industrial partners alongside academic groups, suggesting EVOXX is comfortable operating at the applied end of the research-to-market pipeline. Their participation in projects with 48 partners across 16 countries indicates they are experienced in large multi-partner consortia and can function effectively within complex international project structures.

EVOXX has built connections with 48 unique consortium partners spanning 16 countries through just two projects, indicating they joined large, geographically diverse consortia. No repeated partner patterns can be identified from two projects, but the breadth of the network relative to project count suggests these were substantial European collaborations.

What sets them apart

EVOXX occupies a rare niche as an industrial SME that works across both marine biotech enzyme discovery and applied oxidative biocatalysis — fields that rarely appear in the same organization's portfolio. Unlike academic partners who dominate enzyme research consortia, EVOXX brings an industrial and commercial perspective, making them a natural bridge between fundamental enzyme science and manufacturable bioprocesses. For consortium builders, they represent a credible industrial end-user and application developer with genuine bench-level enzyme expertise.

Highlights from their portfolio

• ROBOX
  EVOXX's largest grant (EUR 312,025), focused on robust oxidative biocatalysts for industrial chemical conversion — a commercially high-value application area at the frontier of green chemistry.
• INMARE
  Addressed the full pipeline from marine extremophile sampling and metagenomic mining through to enzyme expression platforms, making it one of the more complete marine biotech Innovation Actions in H2020.